Abstract: Compounds with 5HT7 receptor affinity (some of which are novel) useful for lowering IOP, improving blood flow to the optic nerve head and the retina, providing neuroprotection, and treating retinal diseases are disclosed. The Compounds are also useful for treating sleep disorders, depression, and other psychiatric disorders, such as, schizophrenia, anxiety, obsessive compulsive disorder, circadian rhythm disorders, and centrally and peripherally mediated hypertension. Compositions and methods for their use are also disclosed.

Abstract: This invention relates to the topical ocular use of non-peptide bradykinin receptor antagonists for the treatment of human ocular pain, neovascularization, corneal haze, allergy and inflammatory diseases.

Abstract: This invention is directed to the use of glutamate antagonists to treat the disorders of outer retina.

Abstract: The invention provides pharmaceutical compositions containing PARP inhibitors and methods of using these compositions to prevent, treat or ameliorate glaucomatous retinopathy and/or optic neuropathy.

Abstract: Methods, for lowering intraocular pressure by implanting in the anterior chamber encapsulated cells which secrete an intraocular pressure lowering substance.

Abstract: Methods and compositions for treating ocular conditions which find their etiology in compromised ocular blood flow with brinzolamide and brimonidine are disclosed.

Abstract: The invention provides pharmaceutical compositions containing calpain inhibitors and methods of using these calpain inhibitors to prevent or ameliorate ocular neural tissue disease or damage.

Abstract: Selective AMPDA inhibitors for preventing and treating damage to the optic nerve and/or retina are disclosed.

Abstract: Methods for treating ocular neovascularization using photodynamic therapy in combination with an angiostatic steriod are disclosed.

Abstract: The invention is directed to the use of improved NR2B antagonists for the prevention and treatment of retinal or optic nerve head damage in mammals. Compositions and methods are disclosed.

Abstract: Methods and compositions for treating ocular conditions which find their etiology in compromised ocular blood flow with brinzolamide and brimonidine are disclosed.

Abstract: Methods for preventing or slowing visual field loss are disclosed.

Abstract: The invention is directed to the use of novel compounds, compositions and methods for the prevention and treatment of neuronal tissue damage in mammals. The novel compounds comprise an antioxidant and a NMDA antagonist activity.

Abstract: Ophthalmic pharmaceutical vehicles which become viscous on contacting the eye are disclosed. Ophthalmic compositions of the vehicle and a pharmaceutically active drug are also disclosed.

Abstract: Methods for preventing and treating corneal haze resulting from exposure of the eye to laser irradiation are disclosed. The methods include administration of compositions of wound healing modulators to the eye. Compositions for use in preventing and treating the corneal haze are also disclosed.

Abstract: Methods for preventing and treating corneal haze resulting from exposure of the eye to laser irradiation are disclosed. The methods include administration of compositions of wound healing modulators to the eye. Compositions for use in preventing and treating the corneal haze are also disclosed.

Abstract: A supplemental intraocular lens is provided for either preoperative or postoperative attachment to a conventional implanted intraocular lens to provide an adjustable or removable multi-focal optic or to provide a necessary optic of spherical, cylindrical or combination shape for refractive error correction in aphakic patients. An intraocular lens system is also provided including a primary intraocular lens modified to provide for securing a supplemental corrective intraocular lens to the primary lens. Either the primary or supplemental lens could be formed of a suitable multi-focal lens, or both lenses could be mono-focal.

Abstract: Methods for treating the cornea following UV laser irradiation and resulting photoablation of corneal tissue are disclosed. The methods include administration of compositions of a non-steroidal antiinflammatory to the eye. Compositions for use in treating the cornea are also disclosed.

Abstract: Disclosed is a process for heat sterilizing pharmaceuticals, cosmetics, foodstuffs and other materials, which are labile to oxidation by atmospheric oxygen at elevated temperature and labile to other degradative changes through interaction with volatiles raised by exposure of the material to elevated temperature, comprising heating, for a given length of time, the material to be sterilized at a temperature required to achieve a predetermined degree of sterilization in a gaseous medium substantially devoid of oxygen; typically such a gaseous medium comprises a non reactive gas, such as, nitrogen, which is otherwise innocuous and capable of being purged at the end of the sterilization process at a pressure sufficient to facilitate the distribution of heat throughout the material being treated by convection.

Abstract: A supplemental intraocular lens is provided for either preoperative or postoperative attachment to a conventional implanted intraocular lens to provide an adjustable or removable multi-focal optic or to provide a necessary optic of spherical, cylindrical or combination shape for refractive error correction in aphakic patients. An intraocular lens system is also provided including a primary intraocular lens modified to provide for securing a supplemental corrective intraocular lens to the primary lens. Either the primary or supplemental lens could be formed of a suitable multi-focal lens, or both lenses could be mono-focal.